Ergomed plc Director/PDMR Shareholding (0319C)
June 13 2019 - 1:01AM
UK Regulatory
TIDMERGO
RNS Number : 0319C
Ergomed plc
13 June 2019
Ergomed Plc
("Ergomed" or the "Company")
PDMR Dealing
Ergomed, a company focused on providing specialised services to
the pharmaceutical industry, announces that on 12 June 2019,
Richard Barfield, Chief Financial Officer of the Company, purchased
64,000 ordinary shares of 1 pence each in the Company ("Share(s)")
at a price of 270 pence per Share (the "Purchase").
Following the Purchase, Richard Barfield's holding in the
Company is 100,000 Shares (representing 0.21 per cent. of the
Company's issued share capital).
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Richard Barfield
--------------------------------------- ------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------------- ------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------
a) Name Ergomed Plc
--------------------------------------- ------------------------------------------------
b) Legal Entity 213800BVS8I9VMC1AP84
Identifier
--------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type
of instrument GB00BN7ZCY67
Identification
code
--------------------------------------- ------------------------------------------------
b) Nature of the Purchase of Shares
transaction
--------------------------------------- ------------------------------------------------
c) Currency GBP
--------------------------------------- ------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------------------- ------------------------- ---------------------
270 pence 64,000
---------------------------------------------------------------------- ---------------------
e) Aggregated information Volume: 64,000 ordinary shares of 1 pence
- Aggregated each, purchase price of 270 pence per share
volume Aggregated: GBP172,800.00
- Price
- Aggregated
total
--------------------------------------- ------------------------------------------------
f) Date of the transaction 12 June 2019
--------------------------------------- ------------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------------------- ------------------------------------------------
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive
Chairman)
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Freddie Barnfield / Huw Jeremy (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services business includes an industry leading suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, and a full range of high-quality contract
research and trial management services under the Ergomed brand
(CRO), and an internationally recognised specialist expertise in
orphan drug development, under PSR. For further information, visit:
http://ergomedplc.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKMGMVNZGGLZM
(END) Dow Jones Newswires
June 13, 2019 02:01 ET (06:01 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024